WIPO logo
Mobile | Deutsch | English | Español | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Recherche dans les collections de brevets nationales et internationales
World Intellectual Property Organization
Recherche
 
Options de navigation
 
Traduction
 
Options
 
Quoi de neuf
 
Connexion
 
Aide
 
maximize
Traduction automatique
1. (WO2015123734) MATERIAUX DE SUPPORT DE LIQUIDES
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

CLAIMS

1. An esterified polysaccharide which is a homopolymer or copolymer comprising esterified sugar monomer units, where the sugar monomer units are esterified ketose or aldose sugars.

2. An esterified polysaccharide which is a homopolymer or copolymer comprising esterified sugar monomer units, where the sugar monomer units are selected from: esterified deoxyribose, esterified arabinose, esterified lyxose, esterified ribose, esterified xylose, esterified ribulose, esterified xyulose, esterified allose, esterified altrose, esterified glucose, esterified 2-deoxy-glucose, esterified mannose, esterified gulose, esterified idose, esterified galactose, esterified talose, esterified psicose, esterified fructose, esterified sorbose, tagatose, or a combination thereof.

3. The esterified polysaccharide according to claim 2, which is a homopolymer or copolymer comprising esterified sugar monomer units, where the sugar monomer units are selected from: esterified 2-deoxyribose, esterified 2-deoxy-D-ribose esterified fructose, esterified galactose, esterified glucose, esterified 2-deoxy-glucose, esterified 2-deoxy-D-glucose, or a mixture thereof.

4. An esterified polysaccharide which is a homopolymer comprising esterified sugar monomer units, wherein the sugar monomer units are esterified 2-deoxyribose monomer units.

5. An esterified polysaccharide which is a homopolymer comprising esterified sugar monomer units, wherein the sugar monomer units are esterified fructose.

6. An esterified polysaccharide which is a homopolymer comprising esterified sugar monomer units, wherein the sugar monomer units are esterified galactose.

7. An esterified polysaccharide which is a homopolymer comprising esterified sugar monomer units, wherein the sugar monomer units are esterified glucose.

8. The esterified polysaccharide according to any one of claims 1 to 7, wherein the esterified sugar monomer prior to esterification promotes angiogenesis.

9. The esterified polysaccharide according to any one of claims 1 to 7, wherein the esterified sugar monomer promotes angiogenesis.

10. The esterified polysaccharide according to any one of claims 1 to 7, wherein the esterified sugar monomer prior to esterification provides anti-angiogenic properties.

11. The esterified polysaccharide according to any one of claims 1 to 7, wherein the esterified sugar monomer provides anti-angiogenic properties.

12. The esterified polysaccharide according to any one of claims 1 to 11, wherein the esterified polysaccharide comprises one type of ester group.

13. The esterified polysaccharide according to any one of claims 1 to 12, wherein the esterified polysaccharide comprises more than one type of ester group.

14. The esterified polysaccharide according to any one of claims 1 to 13, wherein the esterified sugar monomer units co groups of the formula:


wherein R is an alkyl group comprising 1 to 25 carbon atoms.

15. The esterified polysaccharide according to claim 14, wherein the polysaccharide comprises one type of R group.

16. The esterified polysaccharide according to claim 14, wherein the polysaccharide includes more than one type of R group.

17. The esterified polysaccharide according to any one of claims 14 to 16, wherein R is selected from: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, ft-pentyl, ie/t-pentyl, neopentyl, isopentyl, 1-methylbutyl and 1-ethylpropyl, n-hexyl, n-heptyl, or a mixture thereof.

18. The esterified polysaccharide according to any one of claims 14 to 17, wherein R is methyl, ethyl, isopropyl, or a mixture thereof.

19. The esterified polysaccharide according to any one of claims 14 to 18, wherein R is a mixture of methyl and isopropyl.

20. The esterified polysaccharide according to any one of claims 1 to 19, wherein the polysaccharide is a high viscosity liquid carrier material.

21. The esterified polysaccharide according to any one of claims 1 to 20 wherein the polysaccharide has a viscosity of at least 5000 mPa.s at 37 °C.

22. The esterified polysaccharide according to any one of claims 1 to 21, wherein a mixture of the polysaccharide and a solvent has a viscosity of at less than about 1000 mPa.s at 37 °C.

23. The esterified polysaccharide according to claim 22, wherein the viscosity is less than about 200 mPa.s at 37 °C.

24. The esterified polysaccharide according to claim 22 or claim 23, wherein the solvent is selected from: alcohols including ethanol, propanol, and benzyl alcohol; tetraglycol; dimethyl sulfoxide, triacetin, Solketal; N-methyl-2-pyrrolidone, 2-pyrrolidone; esters of carbonic acid and alkyl alcohols including propylene carbonate, ethylene carbonate and dimethyl carbonate; fatty acids including acetic acid, lactic acid and heptanoic acid; alkyl esters of mono-, di-, and tri-carboxylic acids including 2-ethyoxyethyl acetate, ethyl acetate, methyl acetate, ethyl lactate, ethyl butyrate, diethyl malonate, diethyl glutonate, tributyl citrate, diethyl succinate, tributyrin, isopropyl myristate, dimethyl adipate, dimethyl succinate, dimethyl oxalate, dimethyl citrate, triethyl citrate, acetyl tributyl citrate, glyceryl triacetate; alkyl ketones including acetone and methyl ethyl ketone; ether alcohols including 2-ethoxyethanol, ethylene glycol dimethyl ether, glycerol formal; polyhydroxy alcohols including propylene glycol, polyethylene glycol, glycerin, 1,3-butyleneglycol, and isopropylidene glycol (2,2-dimethyl-l,3-dioxolone-4-methanol); dialkylamides including dimethylformamide, dimethylacetamide; dimethylsulfoxide and dimethylsulfone; tetrahydrofuran; lactones including -caprolactone and butyrolactone; cyclic alkyl amides including caprolactam; aromatic amides including N,N-dimethyl-m-toluamide, and l-dodecylazacycloheptan-2-one, or mixtures thereof.

25. The esterified polysaccharide according to any one of claims 21 to 24, wherein the viscosity is measured at 37 °C, recorded at increasing shear rates, using a Physica MCR 301 (Anton Paar) with a gap of 50 μιη.

26. The esterified polysaccharide according to any one of claims 1 to 25, wherein the polysaccharide does not crystallise neat under ambient or physiological conditions.

27. The esterified polysaccharide according to any one of claims 1 to 26, wherein the polysaccharide is phase-transitioning producing a semi- solid depot in vivo.

28. The esterified polysaccharide according to any one of claims 1 to 27, wherein the polysaccharide is biodegradable.

29. The esterified polysaccharide according to any one of claims 1 to 28, wherein the polysaccharide promotes angiogenesis.

30. The esterified polysaccharide according to any one of claims 1 to 28, wherein the polysaccharide provides anti-angio genie properties.

31. The esterified polysaccharide according to any one of claims 1 to 30 wherein the homopolymer or copolymer is produced through a condensation polymerisation followed by an esterification reaction.

32. The esterified polysaccharide according to any one of claims 1 to 31 for healing a wound in a subject.

33. The esterified polysaccharide according to any one of claims 1 to 31 for delivering an agent to a site in or on a subject.

34. The esterified polysaccharide according to claim 33, wherein the subject is an animal.

35. The esterified polysaccharide according to claim 33, wherein the subject is a human being.

36. The esterified polysaccharide according to any one of claims 1 to 31 for promoting bone growth in a subject.

37. A pharmaceutical composition comprising the polysaccharide according to any one of claims 1 to 31, together with one or more pharmaceutically acceptable carriers and/or excipients.

38. The composition according to claim 37, wherein the pharmaceutical composition comprises one or more of the following:

- a solvent; and/or

- one or more agents.

39. The composition according to claim 38, wherein the composition comprises a solvent selected from: alcohols including ethanol, propanol, and benzyl alcohol; tetraglycol; dimethyl sulfoxide, triacetin, Solketal; N-methyl-2-pyrrolidone, 2-pyrrolidone; esters of carbonic acid and alkyl alcohols including propylene carbonate, ethylene carbonate and dimethyl carbonate; fatty acids including acetic acid, lactic acid and heptanoic acid; alkyl esters of mono-, di-, and tri-carboxylic acids including 2-ethyoxyethyl acetate, ethyl acetate, methyl acetate, ethyl lactate, ethyl butyrate, diethyl malonate, diethyl glutonate, tributyl citrate, diethyl succinate, tributyrin, isopropyl myristate, dimethyl adipate, dimethyl succinate, dimethyl oxalate, dimethyl citrate, triethyl citrate, acetyl tributyl citrate, glyceryl triacetate; alkyl ketones including acetone and methyl ethyl ketone; ether alcohols including 2-ethoxyethanol, ethylene glycol dimethyl ether, glycerol formal; polyhydroxy alcohols including propylene glycol, polyethylene glycol, glycerin, 1,3-butyleneglycol, and isopropylidene glycol (2,2-dimethyl- 1 ,3-dioxolone-4-methanol) ; dialkylamides including dimethylformamide, dimethylacetamide; dimethylsulfoxide and dimethylsulfone; tetrahydrofuran; lactones including -caprolactone and butyrolactone; cyclic alkyl amides including caprolactam; aromatic amides including N,N-dimethyl-m-toluamide, and l-dodecylazacycloheptan-2-one, or mixtures thereof.

40. The composition according to claim 38 or claim 39, wherein the composition comprises a solvent selected from ethanol, benzyl alcohol, tetraglycol, or a mixture thereof.

41. The composition according to any one of claims 38 to 40, wherein the solvent is present in an amount of about 10 to about 40% (v/v) relative to the composition as a whole.

42. The composition according to any one of claims 38 to 41, wherein the solvent is present in an amount of about 10 to about 30% (v/v) relative to the composition as a whole.

43. The composition according to any one of claims 33 or 38 to 42, wherein the agent is a bioactive agent selected from: an organic molecule that is a: drug, peptide, protein, carbohydrate, nucleoprotein, mucoprotein, lipoprotein, synthetic polypeptide or protein, small molecule linked to a protein, glycoprotein, steroid, nucleic acid, nucleotide, nucleoside, oligonucleotide, gene, lipid, hormone, vitamin, inorganic compound, or combination thereof.

44. The composition according to claim 43, wherein the bioactive agent causes a biological effect when administered in vivo to a subject.

45. The composition according to any one of claims 38 to claim 44, wherein the composition comprises an agent that is an osteoinductive agent.

46. The composition according to claim 45, wherein the osteoinductive agent is an osteogenic protein, or a growth factor, or a member or the TGF-beta superfamily, or a mixture thereof.

47. The composition according to claim 46, wherein the osteogenic protein is a bone morphogenetic protein (BMP).

48. The composition according to claim 47, wherein the BMP is selected from: BMP-2, BMP-4, BMP-6, BMP-7 (OP-1), and BMP-9, rhBMP-1, rhBMP-2, rhBMP-3, rhBMP-4, rhBMP-5, rhBMP-6, rhBMP-7, rhBMP-8a, rhBMP-8b, rfiBMP-9, rhBMP-10, rhBMP-15, noggin resistant BMPs, or a combination thereof.

49. The composition according to claim 47 or claim 48, wherein the BMP is rhBMP-2 or rhBMP-7.

50. The composition according to any one of claims 45 to 49 wherein the osteoinductive agent is present in an amount of 0.1 to about 40 mg.

51. The composition according to any one of claims 45 to 50 wherein the osteoinductive agent is present in an amount of 0.1 to about 5 mg.

52. The composition according to any one of claims 38 to claim 51, wherein the composition comprises an agent that is an anti-resorptive agent.

53. The composition according to claim 49, wherein the anti-resorptive agent is selected from: a bisphosphonate; IKK inhibitors; osteoprotegerin (OPG); inhibitors of Cathepsin K, chloride ion channel blockers; antibodies directed against RANKL, SOST, and DKK1 ; proton pump inhibitors, or a mixture thereof.

54. The composition according to claim 53, wherein the bisphosphonate is selected from: zoledronic acid, pamidronic acid, ibandronic acid, etidronic acid, alendronic acid, risedronic acid, and tilurondic acid.

55. The composition according to any one of claims 47 to 49, wherein the anti-resorptive agent is selected from: zoledronic acid, OPG, inhibitors of both IKK and

Cathepsin K, anti-RANKL Ab, anti-SOST Ab, and anti DKK1 Ab.

56. The composition according to any one of claims 38 to 55, wherein the composition comprises an agent that is an osteoconductive agent.

57. The composition according to claim 56, wherein the osteoconductive agent is a ceramic particle.

58. The composition according to claim 56 or 57, wherein the osteoconductive agent is selected from: hydroxyapatite, bioglass, silicon substituted hydroxyapatite, porous tri-calcium phosphate, or combinations, composites, or other derivatives of calcium phosphate, or a mixture thereof.

59. The composition according to any one of claims 56 to 58, wherein the osteoconductive agent is hydroxyapatite.

60. The composition according to any one of claims 56 to 59, wherein the osteoconductive agent is present in an amount of about 0.1 to about 10% (w/v).

61. The composition according to any one of claims 56 to 60, wherein the osteoconductive agent is present in an amount of about 1 to about 5% (w/v).

62. The composition according to any one of claims 37 to 61, wherein the composition promotes angiogenesis.

63. The composition according to any one of claims 37 to 61, wherein the composition provides anti-angiogenesis properties.

64. The composition according to any one of claims 37 to 62, wherein the composition comprises an agent that is an angiogenic compound.

65. The composition according to claim 64, wherein the angiogenic compound is selected from: VEGF, nicotinic acid, angiopoietin, erythropoietin (EPO), nicotinic acid and desferoxamine (DFO).

66. The composition according to any one of claims 37 to 65, further comprising a biodegradable polymer.

67. The composition according to claim 66, wherein the biodegradable polymer is selected from: poly(lactic acid) (PLA), including poly(D-lactic acid) (PDLA), poly(lactic -co-glycolic acid) (PLGA), poly(glycolic acid) (PGA), poly( -caprolactone) (PCL), or a mixture thereof.

68. The composition according to any one of claims 37 to 67 for healing a wound in a subject.

69. The composition according to any one of claims 37 to 67 for delivering an agent to a site in or on a subject.

70. The composition according to claim 69, wherein the subject is an animal.

71. The composition according to claim 69, wherein the subject is a human being.

72. The composition according to any one of claims 37 to 67 for promoting bone growth in a subject.

73. A method to promote bone growth, the method comprising providing a composition according to any one of claims 37 to 67 to a site in a subject to promote bone growth at the site.

74. A method to heal wounds in or on a subject, the method comprising providing a composition according to any one of claims 37 to 67, to a wound site in or on the subject to promote healing of the wound.

75. A method to deliver an agent on or in a subject, the method comprising providing a composition according to any one of claims 37 to 67, to a site on or in the subject.

76. The method according to claim 75, wherein the agent is a bioactive agent selected from: an organic molecule that is a: drug, peptide, protein, carbohydrate, nucleoprotein, mucoprotein, lipoprotein, synthetic polypeptide or protein, small molecule linked to a protein, glycoprotein, steroid, nucleic acid, nucleotide, nucleoside, oligonucleotide, gene, lipid, hormone, vitamin, inorganic compound, or combination thereof.

77. The method according to any one of claims 73 to 76, wherein the composition is provided to the site by injection.

78. The method according to claim 73, wherein the site is selected from bone fracture, bone graft, bone wound, bone defect, bone non-union or pseudarthrosis, the spine, surface of a bone implant, or injected within a bone implant, porous scaffold, cage, balloon, membrane, or other containment device.

79. The method according to any one of claims 73 to 78, wherein the subject is an animal.

80. The method according to claim 79, wherein the animal is selected from: warm blooded animals, including mammals, wherein mammals comprises dogs, cats, cattle,

pigs, sheep, goats, rats, guinea pigs, horses, or other bovine, ovine, equine, canine, feline, rodent or murine species; birds; reptiles; fish and amphibians.

81. The method according to any one of claims 73 to 78, wherein the subject is a human being.

82. Use of a composition according to any one of claims 37 to 67 in the preparation of the medicament for promoting bone growth in a subject.

83. Use of a composition according to any one of claims 37 to 67 in the preparation of the medicament for healing wounds in or on a subject.

84. Use of a composition according to any one of claims 37 to 67 in the preparation of the medicament for delivering an agent to a subject.

85. The use according to claim 84, wherein the agent is a bioactive agent selected from: an organic molecule that is a: drug, peptide, protein, carbohydrate, nucleoprotein, mucoprotein, lipoprotein, synthetic polypeptide or protein, small molecule linked to a protein, glycoprotein, steroid, nucleic acid, nucleotide, nucleoside, oligonucleotide, gene, lipid, hormone, vitamin, inorganic compound, or combination thereof.

86. Use of a composition according to any one of claims 37 to 67 for promoting bone growth in a subject.

87. Use of a composition according to any one of claims 37 to 67 for healing wounds in or on a subject.

88. Use of a composition according to any one of claims 37 to 67 to deliver an agent to a subject.

89. The use according to claim 88, wherein the agent is a bioactive agent selected from: an organic molecule that is a: drug, peptide, protein, carbohydrate, nucleoprotein, mucoprotein, lipoprotein, synthetic polypeptide or protein, small molecule linked to a protein, glycoprotein, steroid, nucleic acid, nucleotide, nucleoside, oligonucleotide, gene, lipid, hormone, vitamin, inorganic compound, or combination thereof.

90. The use according to any one of claims 82 to 89, wherein the subject is an animal.

91. The use according to claim 90, wherein the animal is selected from: warm blooded animals, including mammals, wherein mammals comprises dogs, cats, cattle, pigs, sheep, goats, rats, guinea pigs, horses, or other bovine, ovine, equine, canine, feline, rodent or murine species; birds; reptiles; fish and amphibians.

92. The use according to any one of claims 82 to 89, wherein the subject is a human being.

93. A composition according to claim 37 for the controlled release of an agent.

94. An esterified polysaccharide according to any one of claims 1 to 31 for the controlled release of an agent.

95. An esterified polysaccharide according to any one of claims 1 to 31 for the local release of an agent.

96. An esterified polysaccharide used as a high viscosity liquid carrier material.

97. The esterified polysaccharide according to claim 96, wherein the esterified polysaccharide is defined according to any one of claims 1 to 31.

98. The esterified polysaccharide according to claim 96 or claim 97 for the controlled release of an agent.

99. The esterified polysaccharide according to claim 96 or claim 97 for the local release of an agent.

100. A composition for the controlled release of an agent comprising:

- a polymeric high viscosity liquid carrier material; and

- an agent.

101. A composition for the local release of an agent comprising:

- a polymeric high viscosity liquid carrier material; and

an agent.

102. A composition according to claim 96 or 97 wherein the polymeric high viscosity liquid carrier material is an esterified polysaccharide as defined in any one of claims 1 to 31.

103. The composition according to any one of claims 100 to 102, wherein the agent is a bioactive agent selected from: an organic molecule that is a: drug, peptide, protein, carbohydrate, nucleoprotein, mucoprotein, lipoprotein, synthetic polypeptide or protein, small molecule linked to a protein, glycoprotein, steroid, nucleic acid, nucleotide, nucleoside, oligonucleotide, gene, lipid, hormone, vitamin, inorganic compound, or combination thereof.

104. A coating for an implant comprising an esterified polysaccharide as defined in any one of claims 1 to 31.

105. A coating for an implant comprising a composition as defined in any one of claims 37 to 72.

106. The coating for an implant according to claim 104 or claim 105, wherein the implant is an organic material selected from: an autograft, allograft, xenograft or collagen or glycosaminoglycans, proteoglycans, hyaluronic acid or heparin sulphate.

107. The coating for an implant according to claim 104 or claim 105, wherein the implant is a synthetic device selected from: a bone substitute, including a bone substitute made from ceramic, resorbable or non-resorbable polymers, or metal coatings including porous metal coatings of titanium, tantalum, cobalt chrome or stainless steel or their alloys.

108. Use of an esterified polysaccharide as defined in any one of claims 1 to 31 for coating an implant.

109. Use of a composition as defined in any one of claims 37 to 72 for coating an implant.

110. The use according to claim 108 or claim 109, wherein the implant is an organic material selected from: an autograft, allograft, xenograft or collagen or glycosaminoglycans, proteoglycans, hyaluronic acid or heparin sulphate.

111. The use according to claim 108 or claim 109, wherein the implant is a synthetic device selected from: a bone substitute, including a bone substitute made from ceramic, resorbable or non-resorbable polymers, or metal coatings including porous metal coatings of titanium, tantalum, cobalt chrome or stainless steel or their alloys.